Literature DB >> 29765946

Radiation Retinopathy 47 Years following Brachytherapy for Retinoblastoma.

Claudine Bellerive1, Arun D Singh1.   

Abstract

A 50-year-old female who had undergone enucleation in the left eye and brachytherapy in the right eye for retinoblastoma at the age of 2 years was diagnosed with nonproliferation radiation retinopathy 47 years following the initial treatment. The patient had noticed black spots in her vision (scotomas) that interfered with reading. New onset of microaneurysms and lipid exudation threatening the foveola was noted on examination of the right eye. Initial visual acuity (VA) was 20/25. Optical coherence tomography showed no evidence of macular edema, but parafoveal lipid exudation was present. On fluorescein angiography, no sign of neovascularization or macular ischemia was observed. Direct focal treatment of microaneurysms was performed to prevent progression of the radiation retinopathy and vision loss. At 18 months' follow-up following focal laser, VA remained stable at 20/25 and there was a regression of the retinopathy.

Entities:  

Keywords:  Brachytherapy; Radiation retinopathy; Retinoblastoma

Year:  2017        PMID: 29765946      PMCID: PMC5939713          DOI: 10.1159/000481312

Source DB:  PubMed          Journal:  Ocul Oncol Pathol        ISSN: 2296-4657


  15 in total

1.  The conservative treatment of retinoblastoma.

Authors:  H B STALLARD
Journal:  Trans Ophthalmol Soc U K       Date:  1962

2.  Iodine 125 plaque radiotherapy as salvage treatment for retinoblastoma recurrence after chemoreduction in 84 tumors.

Authors:  Carol L Shields; Arman Mashayekhi; Hong Sun; Yusuf Uysal; Jorge Friere; Lydia Komarnicky; Jerry A Shields
Journal:  Ophthalmology       Date:  2006-09-01       Impact factor: 12.079

3.  Long-term visual acuity results of treated and untreated radiation retinopathy (an AOS thesis).

Authors:  James L Kinyoun
Journal:  Trans Am Ophthalmol Soc       Date:  2008

4.  Radiation chorioretinopathy: evidence for effective therapy.

Authors:  Hassan A Aziz; Arun D Singh
Journal:  Int Ophthalmol Clin       Date:  2015

5.  Plaque radiotherapy for retinoblastoma: long-term tumor control and treatment complications in 208 tumors.

Authors:  C L Shields; J A Shields; J Cater; I Othmane; A D Singh; B Micaily
Journal:  Ophthalmology       Date:  2001-11       Impact factor: 12.079

6.  Radiation therapy for retinoblastoma: a retrospective review of 120 patients.

Authors:  D G Pradhan; A L Sandridge; P Mullaney; E Abboud; Z A Karcioglu; A Kandil; M M Mustafa; A J Gray
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-08-01       Impact factor: 7.038

7.  Localized whole eye radiotherapy for retinoblastoma using a (125)I applicator, "claws".

Authors:  C Stannard; R Sealy; E Hering; J Korrubel; J Hill; A Barron; R Knowles
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-10-01       Impact factor: 7.038

8.  The efficacy of focal laser therapy in radiation-induced macular edema.

Authors:  P G Hykin; C L Shields; J A Shields; J F Arevalo
Journal:  Ophthalmology       Date:  1998-08       Impact factor: 12.079

9.  Ocular complications after iodine brachytherapy for large uveal melanomas.

Authors:  Ilkka Puusaari; Jorma Heikkonen; Tero Kivelä
Journal:  Ophthalmology       Date:  2004-09       Impact factor: 12.079

10.  The use of iodine-125 plaques in the treatment of retinoblastoma.

Authors:  C Stannard; R Sealy; D Shackleton; J Hill; J Korrubel
Journal:  Ophthalmic Paediatr Genet       Date:  1987-06
View more
  2 in total

1.  Central Serous Chorioretinopathy in a Case of Regressed Familial Retinoblastoma.

Authors:  Saeed Karimi; Amir Arabi; Toktam Shahraki; Sare Safi
Journal:  J Ophthalmic Vis Res       Date:  2020-10-25

2.  Short-term outcomes following treatment of recalcitrant cystoid macular edema secondary to radiation maculopathy using intravitreal brolucizumab.

Authors:  Giulia Corradetti; Federico Corvi; Alexander Juhn; SriniVas R Sadda
Journal:  Am J Ophthalmol Case Rep       Date:  2020-10-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.